Table of Contents
Bayer and Henry Ford Health have entered a strategic research partnership aimed at expanding access to clinical trials for patients, marking the latest step in this Bayer Henry Ford clinical trials collaboration. The partnership brings together the drugmaker’s global expertise in drug development with the clinical research infrastructure of Henry Ford Health, which has established connections in its regional communities.
What the Bayer Henry Ford Clinical Trials Partnership Will Focus On
Initial activities will target cardiovascular and renal diseases, oncology, and women’s health. Specific areas of focus will include advanced cancers, chronic kidney disease, gynecologic conditions, heart failure, menopausal symptoms, stroke, and thrombosis, aligning closely with the company’s growing pipeline and existing product offerings.
Why Clinical Trials Matter for Patient Access
“Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, chief scientific officer for Henry Ford Health. “Through this collaboration, we aim to make clinical research more accessible, reduce barriers to participation, accelerate the development of new treatments and ensure that more patients have the opportunity to benefit from medical innovation.”
How the Bayer Henry Ford Clinical Trials Collaboration Will Work
Together, the organizations will collaboratively work across the full clinical trial process, using data and technology to design smarter trials, with the goal of allowing patients to access novel treatments sooner by reducing barriers to participation.
Expanding Beyond Traditional Trial Design
Beyond clinical trials, the organizations plan to work together in areas such as using AI, analytics, and electronic health record data to improve trial design and patient identification, generating real-world evidence to better understand how treatments perform, and supporting training and innovation in healthcare data science.
Why Henry Ford Health Was Selected for This Partnership
Henry Ford Health is one of only four academic health systems in the U.S. selected to work with Bayer in this strategic research model, reflecting its clinical expertise, integrated care network, diverse patient population, and strong track record in clinical research. This selective network positions the Bayer Henry Ford clinical trials partnership as part of a broader, deliberate strategy rather than an isolated collaboration.
Part of a Growing Research Network
Earlier in July, the drugmaker announced its first strategic alliance with the University of Colorado Anschutz, UCHealth, and Children’s Hospital Colorado, covering a similar mix of therapeutic areas along with neurodegenerative disease and cell and gene therapy. That deal marked the company’s first structured academic health system research network, and the Henry Ford partnership confirms it is now executing a repeatable model rather than a one-off collaboration.
Henry Ford Health’s Broader Research Portfolio Alongside This Partner
For Henry Ford Health, the partnership adds to a growing list of external collaborations tied to its research and data capabilities, including its earlier work with BD on pharmacy automation and its role within the Truveta real-world data consortium.
A Broader Industry Shift
This tie-up spans cardiovascular and renal disease, oncology, and women’s health, three areas central to Bayer’s current pipeline, and reflects a broader industry shift toward embedding drug developers directly within health systems that serve large, diverse patient populations. Financial terms of the Bayer Henry Ford clinical trials partnership were not disclosed, and no specific drug candidate, technology platform, or clinical trial identifier was named in the announcement.
What This Means for Patients and the Broader Industry
By combining the company’s clinical development capabilities with Henry Ford Health’s trial infrastructure, electronic health record data, and patient population, the partnership aims to improve trial design, identify eligible participants more efficiently, and generate real-world evidence on treatment performance. As Bayer continues building out its network of academic health system partnerships, following its Colorado alliance and now this collaboration in Detroit, it appears to be establishing a scalable, repeatable framework for embedding drug development directly within major U.S. health systems.
What to Watch Going Forward
As the Bayer Henry Ford clinical trials partnership moves from announcement to active trial design and patient enrollment, industry observers will likely watch for how quickly the collaboration produces measurable results in the cardiovascular, oncology, and women’s health areas it targets, as well as whether the drugmaker extends this strategic research network model to additional academic health systems beyond its current four partners.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
